87 patents
Utility
Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
9 Jan 24
Disclosed herein are genome editing systems and related methods which allow for the detection and quantitative measurement of all possible on-target gene editing outcomes, including targeted integration.
Cecilia Cotta-Ramusino, Carrie M. Margulies
Filed: 13 Jul 18
Utility
SYSTEMS AND METHODS FOR ONE-SHOT GUIDE RNA (ogRNA) TARGETING OF ENDOGENOUS AND SOURCE DNA
28 Dec 23
Engineered nucleic acids encoding genome editing system components are provided, as are engineered RNA-guided nucleases that include inserts encoded in part by cellular genomic or other sequences recognized by guide RNAs.
Ari E. Friedland, Hariharan Jayaram, Barrett Ethan Steinberg
Filed: 12 May 23
Utility
CRISPR/CAS-related methods and compositions for treating herpes simplex virus
5 Dec 23
CRISPR/CAS-related systems, compositions and methods for editing RS1, RL2, and/or LAT genes in human cells are described, as are cells and compositions including cells edited according to the same.
Ari E. Friedland, Penrose O'Donnell, David A. Bumcrot
Filed: 19 Apr 21
Utility
Methods for Improving Crispr/cas-mediated Genome-editing
16 Nov 23
This application provides improved methods of editing the genome of a target cell.
Cecilia Cotta-Ramusino
Filed: 25 Apr 23
Utility
Methods and compositions for treating cone-rod retinal dystrophy
7 Nov 23
Provided herein are methods and compositions for treating an eye disorder, for example cone-rod dystrophy type 6 (CORD6).
Shannon E. Boye, Sanford L. Boye, Morgan Maeder
Filed: 28 Aug 18
Utility
Use of Exonucleases to Improve Crispr/cas-mediated Genome Editing
26 Oct 23
The present disclosure is directed to methods of producing a modified nucleic acid comprising a precise deletion in a target nucleic acid in a cell comprising generating, within the cell, a first single strand break on a first strand of the target nucleic acid and a second single strand break on a second strand of the target nucleic acid, thereby forming a double strand break in the target nucleic acid having a first 3′ overhang and a second 3′ overhang; processing the first 3′ overhang and the second 3′ overhang with an exonuclease molecule, thereby deleting the segment of the target nucleic acid that was located between the first single strand break and the second single strand break, and forming a processed double strand break; and allowing the processed double strand break to be repaired by at least one DNA repair pathway, thereby producing the modified nucleic acid comprising the precise deletion in the target nucleic acid in the cell.
Anne Helen Bothmer, Cecilia Cotta-Ramusino, Luis A. Barrera
Filed: 25 Apr 23
Utility
Emulsion-based Screening Methods
5 Oct 23
The present disclosure relates to compositions, systems and methods for analyzing activity of nucleases.
Barrett Ethan Steinberg
Filed: 4 Oct 22
Utility
Compositions and Methods for Treating CEP290-ASSOCIATED Disease
21 Sep 23
Compositions and methods for treatment of CEP290 related diseases are disclosed.
Morgan Lee MAEDER, Rina J. MEPANI, David A. BUMCROT, Shen SHEN, Michael STEFANIDAKIS
Filed: 23 May 22
Utility
Selection by Essential-gene Knock-in
20 Jul 23
Strategies, systems, compositions, and methods for efficient production of knock-in cellular clones without reporter genes.
John Anthony Zuris, Carrie Marie Margulies, Chew-Li Soh, Peter Tonge, Mark James Tomishima, Conor Brian McAuliffe, Claudio Monetti
Filed: 4 May 21
Utility
Systems and methods for one-shot guide RNA (ogRNA) targeting of endogenous and source DNA
4 Jul 23
Engineered nucleic acids encoding genome editing system components are provided, as are engineered RNA-guided nucleases that include inserts encoded in part by cellular genomic or other sequences recognized by guide RNAs.
Ari E. Friedland, Hariharan Jayaram, Barrett Ethan Steinberg
Filed: 27 May 21
Utility
Methods, Compositions and Components for CRISPR-CAS9 Editing of CBLB In T Cells for Immunotherapy
4 May 23
CRISPR/CAS-related genome editing systems, compositions and methods for targeting the CBLB locus, as well as cells edited using these systems, compositions and methods are provided.
Andreia S. COSTA, Jason David FONTENOT, Fred HARBINSKI, Gordon Grant WELSTEAD, Chris WILSON
Filed: 5 Nov 18
Utility
Optimized CRISPR/CAS9 Systems and Methods for Gene Editing In Stem Cells
27 Apr 23
The methods and compositions described herein surprisingly increase CRISPR/Cas-mediated gene editing in stem cells by transiently treating the cells with a stem cell viability enhancer prior to and/or after contacting the cells with one or more CRISPR/Cas9 components.
Jennifer Leah Gori
Filed: 9 Jun 22
Utility
Synthetic Guide Molecules, Compositions and Methods Relating Thereto
13 Apr 23
Chemical syntheses of guide molecules are disclosed, along with compositions and methods relating thereto.
Jim Heil, Stephanie King, Sam Saccomano, Stacy Capehart, Cecilia Fernandez, Hariharan Jayaram, Bruce Eaton, Karin Zemski Berry
Filed: 29 Dec 17
Utility
Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
7 Mar 23
The application provides improved methods of genome editing.
Cecilia Cotta-Ramusino, Anne Helen Bothmer
Filed: 24 Mar 17
Utility
Methods, Compositions and Components for CRISPR-CAS9 Editing of TGFBR2 In T Cells for Immunotherapy
2 Mar 23
CRISPR/CAS-related genome editing systems, compositions and methods for targeting the TGFBR2 locus, as well as cells edited using these systems, compositions and methods are provided.
Stephen Michael BURLEIGH, Melissa CHIN, Fred HARBINSKI, Christopher Heath NYE, Blythe D. SATHER, Queenie VONG, Gordon Grant WELSTEAD, Chris WILSON
Filed: 1 Nov 18
Utility
Engineered Cells for Therapy
16 Feb 23
Methods of culturing embryonic stem cells, induced pluripotent stem cells and/or differentiated cells in culture medium comprising activin are described.
G. Grant Welstead, Jung Il Moon
Filed: 18 Dec 20
Utility
Compositions and Methods for Treating CEP290-ASSOCIATED Disease
9 Feb 23
Compositions and methods for treatment of CEP290 related diseases are disclosed.
Morgan Lee MAEDER, Rina J. MEPANI, David A. BUMCROT, Shen SHEN, Michael STEFANIDAKIS
Filed: 2 Feb 21
Utility
Compositions and methods for treating CEP290 associated disease
31 Jan 23
Nucleic acids and viral vectors, particularly adeno-associated virus (AAV) vectors are provided that encode Cas9 and paired guide RNAs.
Morgan Lee Maeder, Rina J. Mepani, Michael Stefanidakis
Filed: 2 Aug 17
Utility
Crispr/cas-related Methods and Compositions for Treating Leber's Congenital Amaurosis 10 (LCA10)
26 Jan 23
CRISPR/CAS-related compositions and methods for treatment of Leber's Congenital Amaurosis 10 (LCA10) are disclosed.
Morgan Lee MAEDER, David A. BUMCROT, Shen SHEN
Filed: 7 Mar 22
Utility
Crispr/cas-related Methods and Compositions for Treating Sickle Cell Disease
26 Jan 23
CRISPR/CAS-related compositions and methods for treatment of Sickle Cell Disease (SCD) are disclosed.
Ari E. FRIEDLAND, Morgan L. MAEDER, G. Grant WELSTEAD, David A. BUMCROT
Filed: 7 Feb 22